[
  {
    "ts": null,
    "headline": "Walmart earnings in focus, Caesars stock surges, Moderna FDA review",
    "summary": "Yahoo Finance Senior Reporter Brooke DiPalma and Market Domination host Josh Lipton take a look at some of Wednesday's trending tickers and stories. Moderna (MRNA) stock is climbing after the US Food and Drug Administration (FDA) agreed to review the company's new flu shot. Caesars Entertainment (CZR) stock is surging after the company topped fourth quarter earnings expectations. Walmart (WMT) is in focus ahead of the company's anticipated fourth quarter earnings report on Thursday. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=9c2dee6969caeda73975b6a8f6a419879273b9aec488749219ce0feb5bcf6fe2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771448277,
      "headline": "Walmart earnings in focus, Caesars stock surges, Moderna FDA review",
      "id": 139139295,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Yahoo Finance Senior Reporter Brooke DiPalma and Market Domination host Josh Lipton take a look at some of Wednesday's trending tickers and stories. Moderna (MRNA) stock is climbing after the US Food and Drug Administration (FDA) agreed to review the company's new flu shot. Caesars Entertainment (CZR) stock is surging after the company topped fourth quarter earnings expectations. Walmart (WMT) is in focus ahead of the company's anticipated fourth quarter earnings report on Thursday. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=9c2dee6969caeda73975b6a8f6a419879273b9aec488749219ce0feb5bcf6fe2"
    }
  },
  {
    "ts": null,
    "headline": "Why Moderna (MRNA) Stock Is Trading Up Today",
    "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.9% in the afternoon session after the U.S. Food and Drug Administration (FDA) reversed an earlier decision and agreed to review the company's application for its new seasonal flu vaccine.",
    "url": "https://finnhub.io/api/news?id=5f50e4b947d7df61d526c5d591a557a15b9997bb7274d8127e3be8a740730c19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771448162,
      "headline": "Why Moderna (MRNA) Stock Is Trading Up Today",
      "id": 139139488,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.9% in the afternoon session after the U.S. Food and Drug Administration (FDA) reversed an earlier decision and agreed to review the company's application for its new seasonal flu vaccine.",
      "url": "https://finnhub.io/api/news?id=5f50e4b947d7df61d526c5d591a557a15b9997bb7274d8127e3be8a740730c19"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
    "summary": "Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index decreasing 0",
    "url": "https://finnhub.io/api/news?id=74335c58137b18d75507ea6c93622d541a71079b1b5fb5cebefd44e5e6e8f3bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771447563,
      "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
      "id": 139139297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index decreasing 0",
      "url": "https://finnhub.io/api/news?id=74335c58137b18d75507ea6c93622d541a71079b1b5fb5cebefd44e5e6e8f3bf"
    }
  },
  {
    "ts": null,
    "headline": "These S&P500 stocks are moving in today's session",
    "summary": "Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.",
    "url": "https://finnhub.io/api/news?id=14c138b54dbcb964be25fc708992b69712f03163920467a691bfbdfcac065daf",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771445118,
      "headline": "These S&P500 stocks are moving in today's session",
      "id": 139138927,
      "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
      "related": "MRNA",
      "source": "ChartMill",
      "summary": "Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.",
      "url": "https://finnhub.io/api/news?id=14c138b54dbcb964be25fc708992b69712f03163920467a691bfbdfcac065daf"
    }
  },
  {
    "ts": null,
    "headline": "In reversal, US FDA will review Moderna's flu vaccine application",
    "summary": "STORY: The U.S. Food and Drug Administration will review Moderna's modified flu vaccine application, a week after the agency rejected the company's original submission.That's according to the drugmaker, whose shares rose as much as 8.5% Wednesday morning on the news.The FDA's initial refusal to review Moderna's vaccine application had amplified concerns about a sharp shift in U.S. vaccine policy under the Trump administration.That policy, spearheaded by U.S. Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, has contributed to falling vaccination rates and reshaped the regulatory landscape for new shots.In its initial rejection, the FDA said Moderna should have given a higher-strength vaccine to older patients in the control arm of its trial.Moderna said the FDA has now accepted its revised application seeking full approval for the shot for adults aged 50 to 64, and accelerated approval for those aged 65 and above.One analyst told Reuters the agency's about-face potentially brings back a revenue stream for Moderna that \"had been in limbo.\"The HHS, which oversees the FDA, was not immediately available for comment.The FDA is expected to make a decision on the vaccine by August 5.",
    "url": "https://finnhub.io/api/news?id=f5e623ababc1b0cc2175909f0b764a50a414b9b89af9ce3234019b023c3eb6c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771439987,
      "headline": "In reversal, US FDA will review Moderna's flu vaccine application",
      "id": 139138851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "STORY: The U.S. Food and Drug Administration will review Moderna's modified flu vaccine application, a week after the agency rejected the company's original submission.That's according to the drugmaker, whose shares rose as much as 8.5% Wednesday morning on the news.The FDA's initial refusal to review Moderna's vaccine application had amplified concerns about a sharp shift in U.S. vaccine policy under the Trump administration.That policy, spearheaded by U.S. Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, has contributed to falling vaccination rates and reshaped the regulatory landscape for new shots.In its initial rejection, the FDA said Moderna should have given a higher-strength vaccine to older patients in the control arm of its trial.Moderna said the FDA has now accepted its revised application seeking full approval for the shot for adults aged 50 to 64, and accelerated approval for those aged 65 and above.One analyst told Reuters the agency's about-face potentially brings back a revenue stream for Moderna that \"had been in limbo.\"The HHS, which oversees the FDA, was not immediately available for comment.The FDA is expected to make a decision on the vaccine by August 5.",
      "url": "https://finnhub.io/api/news?id=f5e623ababc1b0cc2175909f0b764a50a414b9b89af9ce3234019b023c3eb6c1"
    }
  },
  {
    "ts": null,
    "headline": "Why Moderna Stock Just Popped",
    "summary": "So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy?",
    "url": "https://finnhub.io/api/news?id=f238b574308a4ee06417444b7d7a81a9a1fbd85f7f17de88a949b18242698ca2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771439732,
      "headline": "Why Moderna Stock Just Popped",
      "id": 139138526,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy?",
      "url": "https://finnhub.io/api/news?id=f238b574308a4ee06417444b7d7a81a9a1fbd85f7f17de88a949b18242698ca2"
    }
  },
  {
    "ts": null,
    "headline": "FDA to review Moderna’s flu jab on agency pivot",
    "summary": "The PDUFA date for mRNA-1010 in seasonal influenza is set for 5 August 2026, meaning the vaccine could be on the market for the 2026/2027 flu season.",
    "url": "https://finnhub.io/api/news?id=d98201e941178ae8b6a31c517789a1abac462fef143c833b780947cf5efac99d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771437715,
      "headline": "FDA to review Moderna’s flu jab on agency pivot",
      "id": 139138065,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The PDUFA date for mRNA-1010 in seasonal influenza is set for 5 August 2026, meaning the vaccine could be on the market for the 2026/2027 flu season.",
      "url": "https://finnhub.io/api/news?id=d98201e941178ae8b6a31c517789a1abac462fef143c833b780947cf5efac99d"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Stock Rises. FDA Will Review Its Seasonal Flu Vaccine After All.",
    "summary": "The Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.",
    "url": "https://finnhub.io/api/news?id=f18bd535089920bcc8b847284d594d71cd422de32db02e03d03630c3386561c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771434720,
      "headline": "Moderna Stock Rises. FDA Will Review Its Seasonal Flu Vaccine After All.",
      "id": 139138066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.",
      "url": "https://finnhub.io/api/news?id=f18bd535089920bcc8b847284d594d71cd422de32db02e03d03630c3386561c9"
    }
  },
  {
    "ts": null,
    "headline": "Moderna says FDA to review its flu vaccine after reversing course",
    "summary": "With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.",
    "url": "https://finnhub.io/api/news?id=d98d94f27d1734ceb178709e8600dc0c694470da358f2d99b1b098efec4b3ccc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771434373,
      "headline": "Moderna says FDA to review its flu vaccine after reversing course",
      "id": 139138067,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.",
      "url": "https://finnhub.io/api/news?id=d98d94f27d1734ceb178709e8600dc0c694470da358f2d99b1b098efec4b3ccc"
    }
  },
  {
    "ts": null,
    "headline": "Moderna stock surges as FDA reverses course, agrees to review new flu shot",
    "summary": "Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.",
    "url": "https://finnhub.io/api/news?id=c4cb7d4a4314b76c39337f9d93e75c1233a064321d5c8426589e2b7532efd19c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771431643,
      "headline": "Moderna stock surges as FDA reverses course, agrees to review new flu shot",
      "id": 139137841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.",
      "url": "https://finnhub.io/api/news?id=c4cb7d4a4314b76c39337f9d93e75c1233a064321d5c8426589e2b7532efd19c"
    }
  },
  {
    "ts": null,
    "headline": "Moderna’s investigational flu vaccine moves forward in FDA review",
    "summary": "Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal influenza vaccine, mRNA-1010, following a Type A meeting between the company and the agency. Shares of Moderna added 6.5% at about $47 on the...",
    "url": "https://finnhub.io/api/news?id=56f33ba97c559a9919594ccc37e83e90ab9d5bb83cd8a00a09d84290c684b6e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771431480,
      "headline": "Moderna’s investigational flu vaccine moves forward in FDA review",
      "id": 139138069,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal influenza vaccine, mRNA-1010, following a Type A meeting between the company and the agency. Shares of Moderna added 6.5% at about $47 on the...",
      "url": "https://finnhub.io/api/news?id=56f33ba97c559a9919594ccc37e83e90ab9d5bb83cd8a00a09d84290c684b6e8"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Wednesday: Palo Alto Networks, Analog Devices, Kenvue",
    "summary": "↘️ Palo Alto Networks (PANW): The cybersecurity company posted better-than-expected quarterly results and raised its annual revenue outlook. However, earnings-per-share guidance for this quarter disappointed.",
    "url": "https://finnhub.io/api/news?id=506c6852b1b6eafaf6f0fc4663b90d5c4553042cd0c096e263989bf37f031838",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771407698,
      "headline": "Stocks to Watch Wednesday: Palo Alto Networks, Analog Devices, Kenvue",
      "id": 139132674,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "↘️ Palo Alto Networks (PANW): The cybersecurity company posted better-than-expected quarterly results and raised its annual revenue outlook. However, earnings-per-share guidance for this quarter disappointed.",
      "url": "https://finnhub.io/api/news?id=506c6852b1b6eafaf6f0fc4663b90d5c4553042cd0c096e263989bf37f031838"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma",
    "summary": "Moderna (MRNA) faced a setback in a patent infringement case after a Delaware federal court dismisse",
    "url": "https://finnhub.io/api/news?id=36f4d692cf542d68a5931aeca253b85e0b2fb2381bc073d078b5fc1ab553fb2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771431018,
      "headline": "Moderna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma",
      "id": 139138071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) faced a setback in a patent infringement case after a Delaware federal court dismisse",
      "url": "https://finnhub.io/api/news?id=36f4d692cf542d68a5931aeca253b85e0b2fb2381bc073d078b5fc1ab553fb2e"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ Drugs - Collaborations and Licensing by Key Players Like Moderna, Merck, and IO Biotech",
    "summary": "The cancer vaccine market presents opportunities in personalized and therapeutic vaccines, innovations in delivery strategies, and combination therapies. Collaborations and licensing by key players like Moderna, Merck, and IO Biotech drive industry progression. Challenges remain in broadening efficacy and optimizing delivery platforms.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The \"Cancer Vaccines - Competitive Landscape, 2026\" has been added to ResearchAndMarkets.com's offering. This report offe",
    "url": "https://finnhub.io/api/news?id=7f77633f0c4618287b3fb17926b78d63d2537e42c01bf3c0f73d54e0eb31b08f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771430580,
      "headline": "Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ Drugs - Collaborations and Licensing by Key Players Like Moderna, Merck, and IO Biotech",
      "id": 139137842,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The cancer vaccine market presents opportunities in personalized and therapeutic vaccines, innovations in delivery strategies, and combination therapies. Collaborations and licensing by key players like Moderna, Merck, and IO Biotech drive industry progression. Challenges remain in broadening efficacy and optimizing delivery platforms.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The \"Cancer Vaccines - Competitive Landscape, 2026\" has been added to ResearchAndMarkets.com's offering. This report offe",
      "url": "https://finnhub.io/api/news?id=7f77633f0c4618287b3fb17926b78d63d2537e42c01bf3c0f73d54e0eb31b08f"
    }
  },
  {
    "ts": null,
    "headline": "Wednesday's session: gap up and gap down stock in the S&P500 index",
    "summary": "Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.",
    "url": "https://finnhub.io/api/news?id=b4b8ebdaa09f93b543d3a21de4aaad1f9a2a8a577893bcce6a0e235a5d3feeba",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771428914,
      "headline": "Wednesday's session: gap up and gap down stock in the S&P500 index",
      "id": 139136461,
      "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
      "related": "MRNA",
      "source": "ChartMill",
      "summary": "Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.",
      "url": "https://finnhub.io/api/news?id=b4b8ebdaa09f93b543d3a21de4aaad1f9a2a8a577893bcce6a0e235a5d3feeba"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Today’s Movers: Nvidia, Palantir, Sandisk, Palo Alto, Analog Devices, Garmin, and More",
    "summary": "Nvidia  rose 1.9%.  Facebook owner  Meta Platforms  is expanding its business with the chip designer in a deal likely to be worth tens of billions of dollars.  Meta will use millions of Nvidia’s Blackwell and Rubin graphics processing units, a reminder that Nvidia is still the leading player in artificial-intelligence processors.",
    "url": "https://finnhub.io/api/news?id=01600f34fdbf72612faebd57a117ed4093e6887f3883409794cf4430f138eed8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771418700,
      "headline": "These Stocks Are Today’s Movers: Nvidia, Palantir, Sandisk, Palo Alto, Analog Devices, Garmin, and More",
      "id": 139133936,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Nvidia  rose 1.9%.  Facebook owner  Meta Platforms  is expanding its business with the chip designer in a deal likely to be worth tens of billions of dollars.  Meta will use millions of Nvidia’s Blackwell and Rubin graphics processing units, a reminder that Nvidia is still the leading player in artificial-intelligence processors.",
      "url": "https://finnhub.io/api/news?id=01600f34fdbf72612faebd57a117ed4093e6887f3883409794cf4430f138eed8"
    }
  },
  {
    "ts": null,
    "headline": "Monkeypox Market Competitive Landscape 2026: Comprehensive Insights About 8+ Companies and 10+ Drugs",
    "summary": "Emerging opportunities in the monkeypox treatment and prevention market include innovative vaccine developments by companies such as Bavarian Nordic, BioNTech, and Moderna. The focus is on mRNA-based vaccines and modified vaccines, with numerous clinical trials and strategic collaborations underway to enhance public health responses globally.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The \"Monkeypox - Competitive Landscape, 2026\" has been added to ResearchAndMarkets.com's offering. The \"Monkeypox",
    "url": "https://finnhub.io/api/news?id=982da442360ec8eda0e5ef71eb6bfff411d0f69cd05d24de086149e925b5f0dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771428120,
      "headline": "Monkeypox Market Competitive Landscape 2026: Comprehensive Insights About 8+ Companies and 10+ Drugs",
      "id": 139136854,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Emerging opportunities in the monkeypox treatment and prevention market include innovative vaccine developments by companies such as Bavarian Nordic, BioNTech, and Moderna. The focus is on mRNA-based vaccines and modified vaccines, with numerous clinical trials and strategic collaborations underway to enhance public health responses globally.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The \"Monkeypox - Competitive Landscape, 2026\" has been added to ResearchAndMarkets.com's offering. The \"Monkeypox",
      "url": "https://finnhub.io/api/news?id=982da442360ec8eda0e5ef71eb6bfff411d0f69cd05d24de086149e925b5f0dc"
    }
  },
  {
    "ts": null,
    "headline": "US FDA reverses course, will review Moderna's revised flu vaccine application",
    "summary": "Feb 18 (Reuters) - Moderna said on Wednesday the U.S. drug regulator will review its modified flu vaccine application, a week after rejecting the original submission and fueling industry concerns over",
    "url": "https://finnhub.io/api/news?id=e771b67a0f63e9b6ba26d1b964eff4dc9bba37c9b26469a465d702462e41830c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771426054,
      "headline": "US FDA reverses course, will review Moderna's revised flu vaccine application",
      "id": 139136855,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Feb 18 (Reuters) - Moderna said on Wednesday the U.S. drug regulator will review its modified flu vaccine application, a week after rejecting the original submission and fueling industry concerns over",
      "url": "https://finnhub.io/api/news?id=e771b67a0f63e9b6ba26d1b964eff4dc9bba37c9b26469a465d702462e41830c"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Says FDA Will Review Flu Vaccine, Reversing Earlier Decision. The Stock Is Rising.",
    "summary": "The U.S. Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.",
    "url": "https://finnhub.io/api/news?id=eea18dfa540d8d325c851de31693ad636ed3e416383f29bf4af269c9b9ac68c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771425900,
      "headline": "Moderna Says FDA Will Review Flu Vaccine, Reversing Earlier Decision. The Stock Is Rising.",
      "id": 139136856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The U.S. Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.",
      "url": "https://finnhub.io/api/news?id=eea18dfa540d8d325c851de31693ad636ed3e416383f29bf4af269c9b9ac68c6"
    }
  },
  {
    "ts": null,
    "headline": "Berkshire reduces Apple stake, FDA to review Moderna vaccine",
    "summary": "Morning Brief host Julie Hyman takes a look at some of Wednesday morning's trending tickers and stories. Moderna (MRNA) stock is surging on the US Food and Drug Administration's (FDA's) decision to review the company's flu vaccine, reversing its earlier rejection. New York Times (NYT) stock is on the rise after Berkshire Hathaway (BRK-B, BRK-A) announced a $350 million stake in the news outlet. Berkshire also reduced its stake in Apple (AAPL). Palo Alto Networks (PANW) stock is falling after the company lowered its annual profit forecast. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=da9b06cd04650dc585e9f811245d03fab78e5c7b52dcebf085325c39bd93e3d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771425786,
      "headline": "Berkshire reduces Apple stake, FDA to review Moderna vaccine",
      "id": 139136510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Morning Brief host Julie Hyman takes a look at some of Wednesday morning's trending tickers and stories. Moderna (MRNA) stock is surging on the US Food and Drug Administration's (FDA's) decision to review the company's flu vaccine, reversing its earlier rejection. New York Times (NYT) stock is on the rise after Berkshire Hathaway (BRK-B, BRK-A) announced a $350 million stake in the news outlet. Berkshire also reduced its stake in Apple (AAPL). Palo Alto Networks (PANW) stock is falling after the company lowered its annual profit forecast. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=da9b06cd04650dc585e9f811245d03fab78e5c7b52dcebf085325c39bd93e3d0"
    }
  },
  {
    "ts": null,
    "headline": "FDA Reverses Course and Will Now Review Moderna’s Flu Shot",
    "summary": "The Food and Drug Administration reversed course and agreed to begin a review of  Moderna’s  application to sell a new seasonal flu shot after the vaccine maker agreed to conduct additional testing in the elderly.  The move means that Moderna’s experimental flu shot is largely back on track after the FDA’s surprise decision earlier this month to refuse to start a review of its application.  Moderna said it also met with the FDA and proposed a revised approach.",
    "url": "https://finnhub.io/api/news?id=9c7909449c69dc4646397bd0b5f924c83cf6223fcfc0882723b582a24ad06e1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771423920,
      "headline": "FDA Reverses Course and Will Now Review Moderna’s Flu Shot",
      "id": 139136858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration reversed course and agreed to begin a review of  Moderna’s  application to sell a new seasonal flu shot after the vaccine maker agreed to conduct additional testing in the elderly.  The move means that Moderna’s experimental flu shot is largely back on track after the FDA’s surprise decision earlier this month to refuse to start a review of its application.  Moderna said it also met with the FDA and proposed a revised approach.",
      "url": "https://finnhub.io/api/news?id=9c7909449c69dc4646397bd0b5f924c83cf6223fcfc0882723b582a24ad06e1a"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Jumps After FDA Reverses Decision On Flu Vaccine",
    "summary": "Moderna stock jumped after the Food and Drug Administration reversed its decision not to review the drugmaker's flu vaccine.",
    "url": "https://finnhub.io/api/news?id=eb561cc4debab911ff1882ca70087e5e32d624e829d64c5ef73baf573037a64d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771423361,
      "headline": "Moderna Jumps After FDA Reverses Decision On Flu Vaccine",
      "id": 139136859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna stock jumped after the Food and Drug Administration reversed its decision not to review the drugmaker's flu vaccine.",
      "url": "https://finnhub.io/api/news?id=eb561cc4debab911ff1882ca70087e5e32d624e829d64c5ef73baf573037a64d"
    }
  },
  {
    "ts": null,
    "headline": "What's going on in today's pre-market session: S&P500 movers",
    "summary": "Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.",
    "url": "https://finnhub.io/api/news?id=59d28e4b8f43d03301281cc193f001dbda3968b9a664c45119da8398b65fdbad",
    "source": "ChartMill",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771421708,
      "headline": "What's going on in today's pre-market session: S&P500 movers",
      "id": 139133491,
      "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
      "related": "MRNA",
      "source": "ChartMill",
      "summary": "Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.",
      "url": "https://finnhub.io/api/news?id=59d28e4b8f43d03301281cc193f001dbda3968b9a664c45119da8398b65fdbad"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission",
    "summary": "Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review Moderna has received a Prescription Drug User Fee Act (PDUFA) goal ...",
    "url": "https://finnhub.io/api/news?id=661c8623ef6be4e57ebd18f938b7c7f4f89be048d700b017db1b0ac0d2aba769",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771416000,
      "headline": "Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission",
      "id": 139134555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review Moderna has received a Prescription Drug User Fee Act (PDUFA) goal ...",
      "url": "https://finnhub.io/api/news?id=661c8623ef6be4e57ebd18f938b7c7f4f89be048d700b017db1b0ac0d2aba769"
    }
  },
  {
    "ts": null,
    "headline": "FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal",
    "summary": "The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season.",
    "url": "https://finnhub.io/api/news?id=15ecfffc71f06ee94dbdc6aa1c42240c9266f2e5735b9ca1def96e515833d7a2",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771413435,
      "headline": "FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal",
      "id": 139137408,
      "image": "https://image.cnbcfm.com/api/v1/image/108000894-1771434677666-108000894-1719932078582-gettyimages-2151784856-MODERNA_RSV_VACCINE.jpg?v=1771434697&w=1920&h=1080",
      "related": "MRNA",
      "source": "CNBC",
      "summary": "The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for the upcoming influenza season. ",
      "url": "https://finnhub.io/api/news?id=15ecfffc71f06ee94dbdc6aa1c42240c9266f2e5735b9ca1def96e515833d7a2"
    }
  },
  {
    "ts": null,
    "headline": "Moderna shares are trading higher after the company announced the FDA will initiate the review of its investigational seasonal Influenza vaccine submission.",
    "summary": "Moderna shares are trading higher after the company announced the FDA will initiate the review of its investigational seasonal Influenza vaccine submission.",
    "url": "https://finnhub.io/api/news?id=98eae7ac028525bc9b0dd3398fb22e0677a595992bc2e75007efe63def28d15e",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771408668,
      "headline": "Moderna shares are trading higher after the company announced the FDA will initiate the review of its investigational seasonal Influenza vaccine submission.",
      "id": 139134750,
      "image": "",
      "related": "MRNA",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=98eae7ac028525bc9b0dd3398fb22e0677a595992bc2e75007efe63def28d15e"
    }
  },
  {
    "ts": null,
    "headline": "FDA reverses course on Moderna’s flu vaccine",
    "summary": "Moderna said after a \"Type A\" meeting, the agency agreed to move forward and review its application for the mRNA-based shot.",
    "url": "https://finnhub.io/api/news?id=91c640ac681a0097572cff203829e72d27f155b75a812ca7487de642cfde2d6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771406687,
      "headline": "FDA reverses course on Moderna’s flu vaccine",
      "id": 139138074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna said after a \"Type A\" meeting, the agency agreed to move forward and review its application for the mRNA-based shot.",
      "url": "https://finnhub.io/api/news?id=91c640ac681a0097572cff203829e72d27f155b75a812ca7487de642cfde2d6a"
    }
  },
  {
    "ts": null,
    "headline": "Moderna President Hoge Says We Hope Flu Vaccine Will Be Approved In August; Hope To Have Flu Vaccine On Market In Fall; We Did Agree To Add An Additional Post Marketing Requirement Study",
    "summary": "-Fox Business News",
    "url": "https://finnhub.io/api/news?id=145e0c288fb797cf9458f4176d766367232b98eaa675bf2805e8fa5c20a4323f",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771404234,
      "headline": "Moderna President Hoge Says We Hope Flu Vaccine Will Be Approved In August; Hope To Have Flu Vaccine On Market In Fall; We Did Agree To Add An Additional Post Marketing Requirement Study",
      "id": 139134751,
      "image": "",
      "related": "MRNA",
      "source": "Benzinga",
      "summary": "-Fox Business News",
      "url": "https://finnhub.io/api/news?id=145e0c288fb797cf9458f4176d766367232b98eaa675bf2805e8fa5c20a4323f"
    }
  },
  {
    "ts": null,
    "headline": "Moderna's mRNA-1010 Flu Vaccine Accepted for FDA Review, With Potential Approval in 2026",
    "summary": "Moderna, Inc. (NASDAQ:MRNA) today announced that, in response to a prior Refusal-to-File (RTF) letter, the Company engaged with the U.S. Food and Drug Administration (FDA) in a Type A meeting and proposed a revised",
    "url": "https://finnhub.io/api/news?id=1fed51714dbc46fda10e504920105a0ceadd1b17a3227ff610d3a2aa7f889a72",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771403066,
      "headline": "Moderna's mRNA-1010 Flu Vaccine Accepted for FDA Review, With Potential Approval in 2026",
      "id": 139134752,
      "image": "",
      "related": "MRNA",
      "source": "Benzinga",
      "summary": "Moderna, Inc. (NASDAQ:MRNA) today announced that, in response to a prior Refusal-to-File (RTF) letter, the Company engaged with the U.S. Food and Drug Administration (FDA) in a Type A meeting and proposed a revised",
      "url": "https://finnhub.io/api/news?id=1fed51714dbc46fda10e504920105a0ceadd1b17a3227ff610d3a2aa7f889a72"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks Under $50 with Warning Signs",
    "summary": "Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.",
    "url": "https://finnhub.io/api/news?id=8a45c215429a27cca8c097f146d7baaefc137ee7d5b4e857a3a36ce7ac33714e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771389348,
      "headline": "3 Stocks Under $50 with Warning Signs",
      "id": 139132869,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.",
      "url": "https://finnhub.io/api/news?id=8a45c215429a27cca8c097f146d7baaefc137ee7d5b4e857a3a36ce7ac33714e"
    }
  }
]